Suite 1300
Salt Lake City, UT 84111
Block-1 3rd Floor, Perungudi Bypass Rd, Perungudi,
Chennai - 600096
MGR Main Rd,
Perungudi, Chennai - 600096
Villupuram,
Tamil Nadu – 605602
Oncology Billing for Hospitals
Clinical Service Line — Medical & Radiation Oncology
Chemotherapy J-code billing, drug wastage capture, 340B split-billing compliance, infusion charge accuracy, clinical trial segregation, and prior authorization at scale — for cancer centers that cannot afford revenue leakage.
$200B+
US cancer care spending
annually
40%+
Oncology drug claims denied
without PA on first submission
$500M+
340B savings potential for qualifying
cancer centers annually
Six dimensions where standard RCM falls short in cancer care
High-Cost Drug Reimbursement Risk
A single mis-coded J-code across high-volume infusion represents significant revenue loss. With oncology drugs running thousands of dollars per dose, coding accuracy at the unit, route, and NDC level directly determines margin — and compliance exposure.
Drug Wastage Revenue Opportunity
Modifier JW — used to bill unused portions of single-dose vials — is consistently undercoded at most cancer centers. Accurate wastage capture is both a CMS compliance requirement and a substantial ongoing revenue recovery opportunity.
Prior Authorization at Every Cycle
Most commercial payers and Medicare Advantage plans require PA for each chemotherapy regimen and often for each treatment cycle. High-volume infusion centers managing dozens of active patients face constant authorization pressure with direct impact on cash flow and treatment access
340B Compliance Complexity
Split-billing workflows require separate identification of 340B-purchased drugs (modifier JG) and non-340B drugs (modifier TB). Incorrect modifier application creates OIG audit exposure and overpayment liability — putting the financial benefit of 340B participation at risk.
Clinical Trial Billing Segregation
Medicare Coverage Analysis must precede each trial protocol. Errors in routine care vs. research cost segregation create either non-payment or False Claims Act risk. Both outcomes are unacceptable — and both require specialized expertise to prevent
Continuous Coding Environment
FDA approves new oncology agents continuously. The lag between FDA approval and HCPCS J-code assignment means frequent NOC billing, quarterly code updates, and payer policy changes — requiring coders with dedicated, ongoing oncology expertise.
Where oncology revenue leaks and where AnnexMed intervenes
Chemotherapy J-Code & Drug Wastage Billing
Hundreds of oncology drugs carry individual HCPCS J-codes. Dosage calculation, unit conversion, NDC reporting, route-of-administration modifiers, and modifier JW for drug wastage must all be accurate on every claim. Errors at scale represent significant revenue loss and compliance exposure — with no tolerance for approximation in high-cost drug reimbursement.
Prior Authorization at Every Treatment Cycle
Commercial payers and Medicare Advantage plans require PA for each chemotherapy regimen — and often each cycle. High-volume infusion centers managing dozens of active patients across multiple concurrent regimens face a full-time authorization challenge with direct impact on treatment continuity and cash flow.
340B Split-Billing Compliance
Hospitals with 340B eligibility must maintain separate billing streams for 340B-purchased drugs (modifier JG) and non-340B drugs (modifier TB). Incorrect modifier application generates OIG audit exposure and overpayment liability. Correct 340B billing directly protects and monetizes program savings — making split-billing accuracy a financial performance issue, not just a compliance issue.
Clinical Trial Billing Segregation
Medicare Coverage Analysis must precede each trial to determine which costs are covered as routine care vs. research costs. Incorrect allocation results in either non-payment or False Claims Act exposure — the latter representing a principal compliance risk for oncology programs. Correct trial billing requires protocol-specific expertise and meticulous documentation.
Radiation Oncology Billing Complexity
IMRT, SBRT, IGRT, proton therapy, and brachytherapy each have distinct CPT billing frameworks with technical and professional components. Simulation, treatment planning, dosimetry, and treatment delivery are all separately billable — and separately auditable by payers. Incorrect component billing misrepresents the full cost of radiation oncology care.
New Drug Coding Lag & NOC Billing
FDA approves new oncology agents continuously. The lag between FDA approval and HCPCS J-code assignment means new drugs must be billed as NOC codes (J9999/C9399) with complete drug name, NDC, dosage, and route documentation — a process prone to payer disputes and payment delays without specialized oncology billing expertise.
Enhancing Oncology Model (EOM) Reporting
CMS's EOM replaces the Oncology Care Model with enhanced requirements for quality reporting, patient navigation documentation, and care plan compliance. Participating practices must maintain structured EOM reporting alongside standard FFS claims — adding operational load without additional reimbursement unless managed efficiently.
AnnexMed provides the following specialized RCM services for oncology facilities and cancer center programs:
Chemotherapy J-Code & Drug Wastage Billing
Complete chemotherapy drug billing across all HCPCS J-codes: dosage calculation, unit conversion, NDC reporting, route-of-administration modifiers, modifier JW for drug wastage capture, and modifier JZ where no wastage occurs. Includes NOC code billing for newly approved agents awaiting J-code assignment — with complete drug name, NDC, and dosage documentation.
Oncology Prior Authorization Management
Complete chemotherapy drug billing across all HCPCS J-codes: dosage calculation, unit conversion, NDC reporting, route-of-administration modifiers, modifier JW for drug wastage capture, and modifier JZ where no wastage occurs. Includes NOC code billing for newly approved agents awaiting J-code assignment — with complete drug name, NDC, and dosage documentation.
340B Program Split-Billing
Split-billing workflows with correct modifier application (JG/TB), 340B vs. non-340B drug identification at point of claim, audit documentation maintenance for OIG compliance, and quarterly 340B billing accuracy reviews — protecting the financial savings of program participation and keeping clients ahead of OIG scrutiny.
Infusion Center Administration Billing
Drug administration CPT coding across the full infusion hierarchy: first-hour infusion, each additional hour, therapeutic push, and injection — with NCCI edit compliance, payer-specific bundling rule management, and retrospective charge capture audits to identify underbilled infusion encounters and administration sequences
Radiation Oncology Billing
Technical and professional component billing for IMRT, SBRT, IGRT, brachytherapy, and proton therapy — including simulation, treatment planning, dosimetry, and treatment delivery codes. Correct TC/26 modifier application, payer-specific coverage verification, and radiation plan documentation review ensure full capture across the radiation oncology episode of care.
Clinical Trial Billing Compliance
Medicare Coverage Analysis documentation review, routine care vs. research cost segregation, modifier Q0/Q1 application, and coverage determination documentation — protecting oncology programs from both payment denial and False Claims Act exposure. Protocol-specific billing review ensures each trial is billed to its correct coverage category from the first claim forward.
Bone Marrow Transplant Billing
High-complexity BMT facility and professional billing including preparative regimen coding, transplant procedure billing, and post-transplant care management with correct DRG assignment, diagnosis sequencing, and coordination with hematology professional fee billing — across autologous, allogeneic, and haploidentical transplant types.
Surgical Oncology Billing
Oncology surgical procedure billing with CDI support for cancer-specific DRGs, coordination with anatomic and intraoperative pathology billing, and post-surgical oncologic follow-up coding — ensuring complete charge capture across the surgical episode and correct payer classification for oncologic resections.
EOM / OCM Reporting Support
Alternative payment model reporting for Enhancing Oncology Model participants: quality metric tracking, care plan documentation compliance, patient navigation reporting, and 24/7 access documentation — managed alongside standard FFS billing operations from a single RCM partner without adding internal administrative burden.
Oncology-specific billing dimensions & AnnexMed approach
Billing Dimension
Detail & AnnexMed Approach
Claim Form
UB-04 (infusion facility / hospital outpatient); CMS-1500 (medical oncologist professional component)
Drug Billing
HCPCS J-codes (J0000–J9999); NDC required on all drug claims; units = dosage ÷ J-code unit size; quarterly HCPCS updates monitored
Drug Wastage
Modifier JW = unused portion of single-dose vial billed; modifier JZ = no wastage; both required for CMS compliance and revenue capture
NOC Billing
J9999 / C9399 for newly approved agents without J-codes; complete drug name, NDC, dosage, and route required to avoid payer rejection
Administration Codes
CPT 96401–96549; infusion hierarchy: first hour, each additional, therapeutic push, injection — with NCCI edit and bundling compliance
340B Modifiers
JG = 340B-purchased drug; TB = non-340B drug — required on all drug claims for 340B-participating hospitals; OIG audit documentation maintained
Radiation CPTs
77300–77799 (technical component); 77XX (physician planning / management) — separate TC/26 modifier billing for each radiation episode
Clinical Trial Modifiers
Q0 = routine clinical trial service; Q1 = medically necessary non-trial service in a trial patient — Medicare Coverage Analysis required before each trial
EOM Requirements
Monthly care plan, patient navigation, and 24/7 clinical access documentation required for EOM participation — tracked alongside standard FFS billing
Top Denial Types
PA failure, NDC error, JW modifier omission, 340B modifier dispute, clinical trial cost allocation error, infusion hierarchy sequencing, radiation component mismatch
Measurable financial outcomes for cancer centers
Drug Reimbursement
Improved high-cost drug reimbursement accuracy through J-code unit precision, NDC compliance, and NOC billing protocols for newly approved agents
Drug Wastage Capture
Retrospective audits identify underbilled JW modifier opportunities; prospective workflows prevent ongoing wastage revenue loss from single-dose vial billing
Infusion Charge Capture
Comprehensive infusion hierarchy coding (CPT 96401–96549) ensures all administration services are captured with correct first-hour and sequential coding across multi-drug regimens
Chemo Denial Reduction
Proactive PA management, payer-specific submission protocols, and cycle renewal tracking reduce chemotherapy denial rates and accelerate reimbursement cycles
340B Program Value
Correct JG/TB modifier workflows protect 340B program savings and maintain OIG compliance — preserving the substantial cost differential between 340B drug acquisition and payer reimbursement
Revenue Integrity
Clinical trial billing compliance and radiation oncology component billing protect against False Claims Act exposure and audit-related revenue recoupment
Why AnnexMed for oncology revenue cycle?
J-Code & Quarterly Update Expertise
AnnexMed oncology billing team maintains current J-code expertise through quarterly HCPCS update training, ensuring every new drug approval and code change is reflected in billing before the first claim is submitted. This protects reimbursement accuracy on high-cost agents from day one.
Drug Wastage Revenue Recovery
Our drug wastage billing program (modifier JW) captures revenue that most oncology programs leave unrecovered. We conduct retrospective charge audits to identify underbilled wastage, and establish prospective workflows that protect this revenue stream across all single-dose vial administrations going forward.
PA Pipeline Management
Our PA management system tracks authorization status by patient, regimen, cycle, and payer, giving oncology program administrators real-time visibility into the full PA pipeline and preventing treatment delays caused by billing-related authorization failures or cycle renewal gaps.
Proactive 340B Compliance
340B compliance is a proactive discipline at AnnexMed. We implement split-billing workflows, maintain OIG-grade modifier audit documentation, and conduct quarterly 340B billing accuracy reviews, keeping clients ahead of OIG scrutiny and preserving the full financial benefit of 340B program participation.
Clinical Trial Billing Protection
Clinical trial billing compliance is a dedicated service at AnnexMed. Our specialists perform Coverage Analysis documentation review, maintain routine vs. research cost segregation, and apply correct Q0/Q1 modifiers to prevent both payment denial and False Claims Act exposure across every active trial protocol.
EOM Reporting Alongside FFS Billing
AnnexMed manages Enhancing Oncology Model reporting requirements alongside standard fee-for-service billing, giving oncology programs a single partner for revenue cycle operations, quality reporting compliance, and alternative payment model participation without adding internal administrative burden.
Dedicated Oncology Account Specialists
Dedicated account management by a hospital oncology RCM specialist, not a rotating call center, provides strategic performance oversight, proactive denial analysis, and quarterly revenue integrity reviews from day one of the engagement.
Ready to optimize your oncology revenue cycle?
Discover how much revenue your cancer center may be leaving unrealized — from drug wastage undercoding to 340B compliance gaps and infusion charge capture failures. Get a customized oncology RCM performance review from specialists who understand the full complexity of cancer center billing.
Trusted by 100+ Healthcare Providers | AAPC, AHIMA & AAHAM Certified | SOC 2 Type II | All 50 States
Case Studies
See the impact we deliver
Discover how AnnexMed reduces denials, accelerates reimbursements, and strengthens financial performance. Backed by measurable outcomes and proven RCM expertise, we deliver operational excellence, revenue stability, and sustainable growth you can trust.
Client Voices
See how our clients succeed
Proven RCM expertise. Delivered at scale.
For over 20 years, AnnexMed has delivered RCM solutions nationwide, combining expert billing, coding, and AR support to drive measurable results and growth.
- 20+ years of proven healthcare RCM experience
- 1,500+ professionals supporting billing, coding & AR
- 500+ certified coders across multiple specialties
- 99%+ compliance with HIPAA and security standards
- All 50 states served with consistent, scalable operations
